Verastem Inc - Understand $vstm stock

$VSTM Market Cap: $109.1 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$10.00M

TTM

Gross Margin

Net Earnings

-$89.49M

TTM

Current Assets

$99.65M

Q2 2024

Current Liabilities

$30.35M

Q2 2024

Current Ratio

328.36%

Q2 2024

Total Assets

$105.7M

Q2 2024

Total Liabilities

$65.74M

Q2 2024

Book Value

$40.01M

Q2 2024

Cash

$83.37M

Q2 2024

P/E

-1.219

Sep 18, 2024 EST

Free Cash Flow

-$85.59M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Revenue	$0.00	$2.596M	$2.053M	$88.52M	$17.46M	$26.72M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-100.0%	26.45%	-97.68%	407.08%	-34.67%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Revenue	$0.00	$2.596M	$2.053M	$88.52M	$17.46M	$26.72M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue		$0.00	$0.00	$32.95M	$1.240M	$170.0K
Gross Profit		$2.596M	$2.053M	$55.56M	$16.22M	$26.55M
Gross Profit Margin		100.0%	100.0%	62.77%	92.92%	99.37%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Selling, General & Admin	$30.73M	$24.98M	$24.12M	$62.76M	$101.2M	$77.27M	$21.38M	$17.22M	$17.63M	$18.16M	$15.47M	$10.52M	$3.820M	$380.0K
YoY Change	23.04%	3.57%	-61.57%	-38.0%	30.99%	261.39%	24.16%	-2.33%	-2.92%	17.39%	47.05%	175.39%	905.26%
% of Gross Profit		962.06%	1174.62%	112.95%	624.0%	291.02%
Research & Development	$61.36M	$50.56M	$39.35M	$41.38M	$45.78M	$43.65M	$46.42M	$19.78M	$40.57M	$35.45M	$25.93M	$21.71M	$9.883M	$400.0K
YoY Change	21.36%	28.49%	-4.9%	-9.62%	4.88%	-5.97%	134.68%	-51.24%	14.44%	36.71%	19.43%	119.69%	2370.75%
% of Gross Profit		1947.53%	1916.56%	74.47%	282.23%	164.4%
Depreciation & Amortization	$100.0K	$100.0K	$200.0K	$500.0K	$400.0K	$1.000M	$560.0K	$670.0K	$750.0K	$430.0K	$236.0K	$207.0K	$83.00K	$0.00
YoY Change	0.0%	-50.0%	-60.0%	25.0%	-60.0%	78.57%	-16.42%	-10.67%	74.42%	82.2%	14.01%	149.4%
% of Gross Profit		3.85%	9.74%	0.9%	2.47%	3.77%
Operating Expenses	$92.08M	$75.53M	$63.46M	$104.1M	$147.0M	$120.9M	$67.80M	$37.00M	$58.20M	$53.61M	$41.40M	$32.23M	$13.70M	$780.0K
YoY Change	21.91%	19.02%	-39.06%	-29.16%	21.57%	78.34%	83.24%	-36.43%	8.56%	29.49%	28.46%	135.29%	1656.15%
Operating Profit	-$92.08M	-$72.94M	-$61.41M	-$49.36M	-$132.3M	-$94.78M					-$41.40M	-$32.23M	-$13.70M
YoY Change	26.25%	18.77%	24.41%	-62.7%	39.63%						28.46%	135.29%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Interest Expense	$4.139M	$2.137M	$9.972M	$15.79M	$20.61M	$5.810M	$0.00	$560.0K	$330.0K	$240.0K	$200.0K	$250.0K	$20.00K	$0.00
YoY Change	93.68%	-78.57%	-36.86%	-23.36%	254.7%		-100.0%	69.7%	37.5%	20.0%	-20.0%	1150.0%
% of Operating Profit
Other Income/Expense, Net	-$109.0K	$47.00K	$0.00	-$1.313M	-$641.0K	$25.56M
YoY Change	-331.91%		-100.0%	104.84%	-102.51%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Pretax Income	-$87.37M	-$73.81M	-$71.20M	-$67.53M	-$149.2M	-$72.43M	-$67.80M	-$36.44M	-$57.87M	-$53.37M	-$41.20M	-$31.98M	-$13.68M	-$780.0K
YoY Change	18.36%	3.67%	5.43%	-54.74%	105.99%	6.83%	86.06%	-37.03%	8.43%	29.54%	28.83%	133.77%	1653.85%
Income Tax		$0.00	$0.00	$194.0K	$0.00	$0.00					$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$87.37M	-$73.81M	-$71.20M	-$67.73M	-$149.2M	-$72.43M	-$67.80M	-$36.44M	-$57.87M	-$53.37M	-$41.20M	-$31.98M	-$13.68M	-$780.0K
YoY Change	18.36%	3.67%	5.13%	-54.61%	105.99%	6.83%	86.06%	-37.03%	8.43%	29.53%	28.82%	133.75%	1654.23%
Net Earnings / Revenue		-2843.3%	-3468.1%	-76.51%	-854.77%	-271.11%
Basic Earnings Per Share	-$3.96	-$0.38	-$0.41	-$0.44	-$2.00	-$1.12
Diluted Earnings Per Share	-$3.93	-$0.38	-$0.41	-$0.44	-$2.00	-$1.37	-$1.765M	-$985.1K	-$1.611M	-$2.069M	-$1.817M	-$1.704M	-$676.2K	-$38.56K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Cash & Short-Term Investments	$137.1M	$87.89M	$100.3M	$141.2M	$75.50M	$249.7M	$86.70M	$80.90M	$110.3M	$92.70M	$101.3M	$56.60M	$47.80M	$3.600M
YoY Change	56.02%	-12.33%	-29.0%	87.02%	-69.76%	188.0%	7.17%	-26.65%	18.99%	-8.49%	78.98%	18.41%	1227.78%
Cash & Equivalents	$77.91M	$74.93M	$21.25M	$67.80M	$43.50M	$129.9M	$82.20M	$32.30M	$24.90M	$33.90M	$18.90M	$10.10M	$21.00M	$3.600M
Short-Term Investments	$59.22M	$12.96M	$79.00M	$73.40M	$32.00M	$119.8M	$4.500M	$48.50M	$85.40M	$58.80M	$82.40M	$46.50M	$26.90M	$0.00
Other Short-Term Assets	$6.553M	$4.945M	$4.968M	$3.500M	$3.800M	$3.000M	$1.100M	$200.0K	$400.0K	$300.0K	$500.0K	$300.0K	$100.0K	$0.00
YoY Change	32.52%	-0.46%	41.94%	-7.89%	26.67%	172.73%	450.0%	-50.0%	33.33%	-40.0%	66.67%	200.0%
Inventory				$0.00	$3.100M	$300.0K
Prepaid Expenses
Receivables	$0.00	$31.00K	$516.0K	$200.0K	$2.500M	$300.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$143.7M	$92.87M	$105.7M	$144.9M	$85.00M	$253.3M	$87.80M	$81.30M	$110.8M	$95.30M	$102.0M	$57.10M	$47.90M	$3.600M
YoY Change	54.71%	-12.17%	-27.03%	70.47%	-66.44%	188.5%	8.0%	-26.62%	16.26%	-6.57%	78.63%	19.21%	1230.56%
Property, Plant & Equipment	$1.208M	$1.881M	$2.512M	$3.100M	$4.000M	$1.400M	$900.0K	$1.400M	$2.000M	$2.800M	$600.0K	$800.0K	$700.0K	$0.00
YoY Change	-35.78%	-25.12%	-18.97%	-22.5%	185.71%	55.56%	-35.71%	-30.0%	-28.57%	366.67%	-25.0%	14.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00	$6.000M						$0.00	$22.30M	$34.90M	$9.000M	$0.00
YoY Change			-100.0%							-100.0%	-36.1%	287.78%
Other Assets	$4.828M	$299.0K	$410.0K	$300.0K	$36.10M	$1.000M	$1.100M	$900.0K	$200.0K	$500.0K	$300.0K	$100.0K	$1.400M	$0.00
YoY Change	1514.72%	-27.07%	36.67%	-99.17%	3510.0%	-9.09%	22.22%	350.0%	-60.0%	66.67%	200.0%	-92.86%
Total Long-Term Assets	$6.036M	$2.180M	$2.922M	$9.400M	$60.00M	$23.90M	$2.000M	$2.300M	$2.300M	$3.300M	$23.30M	$35.80M	$11.10M	$0.00
YoY Change	176.88%	-25.39%	-68.91%	-84.33%	151.05%	1095.0%	-13.04%	0.0%	-30.3%	-85.84%	-34.92%	222.52%
Total Assets	$149.7M	$95.05M	$108.7M	$154.3M	$145.0M	$277.2M	$89.80M	$83.60M	$113.1M	$98.60M	$125.3M	$92.90M	$59.00M	$3.600M
YoY Change
Accounts Payable	$7.184M	$4.901M	$2.302M	$1.900M	$9.700M	$10.30M	$9.200M	$4.100M	$3.900M	$3.200M	$2.800M	$1.800M	$2.300M	$300.0K
YoY Change	46.58%	112.9%	21.16%	-80.41%	-5.83%	11.96%	124.39%	5.13%	21.88%	14.29%	55.56%	-21.74%	666.67%
Accrued Expenses	$18.87M	$15.78M	$16.29M	$15.20M	$19.80M	$21.10M	$7.800M	$6.700M	$5.900M	$5.400M	$4.300M	$500.0K	$800.0K	$100.0K
YoY Change	19.6%	-3.14%	7.16%	-23.23%	-6.16%	170.51%	16.42%	13.56%	9.26%	25.58%	760.0%	-37.5%	700.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$275.0K			$0.00	$5.700M
YoY Change	-100.0%				-100.0%
Total Short-Term Liabilities	$26.38M	$21.66M	$18.59M	$17.10M	$29.90M	$37.10M	$17.10M	$11.00M	$10.10M	$9.200M	$7.800M	$2.400M	$3.100M	$400.0K
YoY Change	21.77%	16.53%	8.71%	-42.81%	-19.41%	116.96%	55.45%	8.91%	9.78%	17.95%	225.0%	-22.58%	675.0%
Long-Term Debt	$40.09M	$24.53M	$249.0K	$19.10M	$103.6M	$114.7M	$14.80M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	63.44%	9749.8%	-98.7%	-81.56%	-9.68%	675.0%
Other Long-Term Liabilities	$4.719M	$1.470M	$2.264M	$2.900M	$4.400M	$1.100M	$200.0K	$300.0K	$500.0K	$700.0K	$0.00	$100.0K	$500.0K	$0.00
YoY Change	221.02%	-35.07%	-21.93%	-34.09%	300.0%	450.0%	-33.33%	-40.0%	-28.57%		-100.0%	-80.0%
Total Long-Term Liabilities	$44.81M	$26.00M	$2.513M	$22.00M	$108.0M	$115.8M	$15.00M	$300.0K	$500.0K	$700.0K	$0.00	$100.0K	$500.0K	$0.00
YoY Change	72.35%	934.46%	-88.58%	-79.63%	-6.74%	672.0%	4900.0%	-40.0%	-28.57%		-100.0%	-80.0%
Total Liabilities	$71.19M	$47.66M	$21.10M	$39.10M	$137.9M	$152.9M	$32.10M	$11.30M	$10.60M	$9.900M	$7.800M	$2.500M	$3.700M	$400.0K
YoY Change	49.36%	125.84%	-46.03%	-71.65%	-9.81%	376.32%	184.07%	6.6%	7.07%	26.92%	212.0%	-32.43%	825.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018
Basic Shares Outstanding	22.05M	193.7M	174.4M	153.3M	74.58M	64.96M
Diluted Shares Outstanding	22.05M	193.7K	174.4M	153.3M	74.58M	69.32M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $109.06 Million

About Verastem Inc

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 73 full-time employees. The company went IPO on 2011-11-08. The firm's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).

Industry: Pharmaceutical Preparations Peers: Actinium Pharmaceuticals Inc Acumen Pharmaceuticals Inc Akouos, Inc. Armata Pharmaceuticals Inc Ardelyx Inc LENZ Therapeutics Inc Oyster Point Pharma, Inc. ARS Pharmaceuticals Inc